Keytruda pembrolizumab: Preliminary Phase II data

Preliminary data from 50 evaluable patients with recurrent or metastatic SCCHN who progressed on platinum-based therapy and cetuximab in the open-label Phase II

Read the full 230 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE